RxDoctor Payments Data

Royal Dean, MD

General Practice · Simi Valley, CANPI 1417976945

Payments from drug & device makers

$159in general payments, 2019–2025

Across 6 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$74
  • Novartis$23
  • AstraZeneca$21
  • Sanofi-aventis U.S. LLC$16
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$14
  • AbbVie$12

What the payments were for

  • Food & beverage$159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$159 in reported general payments places this provider in the 40th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$305,904
Medicare patients
430
Services billed
2,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide193$235,985
EliquisApixaban91$57,818
JanuviaSitagliptin Phosphate39$38,063
JardianceEmpagliflozin34$28,870
FarxigaDapagliflozin Propanediol31$26,560
JanumetSitagliptin Phos/Metformin Hcl14$9,951
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$8,853
MyrbetriqMirabegron12$7,797
Testosterone34$6,946
TradjentaLinagliptin14$6,716
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,944
Dexlansoprazole DrDexlansoprazole13$5,071
Levothyroxine Sodium456$4,328
Gabapentin192$4,312
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$21$26,56031 claims
AbbVieSynthroid$12$3,62484 claims
Sanofi-aventis U.S. LLCLantus$16$1,77119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 12,963 general practice providers in California.

Other general practice in Simi Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →